| Orteronel | |
|---|---|
|
6-(7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methylnaphthalene-2-carboxamide |
|
|
Other names
TAK-700 |
|
| Identifiers | |
| CAS number | 566939-85-3 |
| PubChem | 9883029 |
| ChemSpider | 8058704 |
| UNII | UE5K2FNS92 |
| Jmol-3D images | Image 1 |
|
|
|
|
| Properties | |
| Molecular formula | C18H17N3O2 |
| Molar mass | 307.35 g mol−1 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
Orteronel (TAK-700) is an experimental drug for the treatment of cancer under development by Millennium Pharmaceuticals.[1] It is currently in Phase III clinical trials for metastatic, hormone-refractory prostate cancer.[2]
Orteronel is an inhibitor of the enzyme CYP17A1.[3]